Navigation Links
New Study Reports Improved Patient Outcomes for Breast Cancer Patients
Date:2/18/2009

chieve the desired outcome in 54 percent of the cases while 46 percent required additional surgeries because of the 5mm requirement. Survival rates for patients undergoing this treatment at Henry Mayo compared favorably with data presented by the National Council Database reporting on outcomes at teaching/research hospitals. Disease free survival for early stage cancer was 91 percent at five years.

The flap-advancement reconstruction surgery performed by Dr. Senofsky requires a team that includes a specially trained surgeon and radiologist plus the presence of a pathologist in the operating room to provide real-time information. "The procedure requires extra work and extra training in how radiologists insert the wires and how surgeons approach their craft relative to performing larger targeted lumpectomies with excellent cosmetic results, but it is what patients should come to expect based on our study," he said.

"It is difficult to successfully obtain adequate excision of the cancer while still maintaining a beautiful breast with no distortions--and that's very important to a woman," stated Dr. Florentine. "Dr. Senofsky is able to achieve both through the use of oncoplastic techniques."

While Henry Mayo has no comprehensive breast center building, the hospital does provide equivalent services thanks to a well-integrated medical campus and a multi-modality breast team that meets regularly to discuss care plans tailored to the uniqueness of each patient, including age, health status, risk factors, and the patient's own desires and needs. The hospital owns and operates the pathology, breast imaging, and inpatient and outpatient surgical operating suites while on-campus radiation, medical oncology and breast surgery services are provided by independent physician groups.

The study was conducted by a nine-person investigative team, six of whom are affiliated with Henry Mayo. Leading the study were Drs.
'/>"/>

SOURCE Henry Mayo Newhall Memorial Hospital
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
3. Kline Study: Better Brushing Habits Boost European Oral Care Sales
4. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
5. NASA study will help stop stowaways to Mars
6. New Study Findings Confirm CLEXANE(R)/LOVENOX(R) Long-Term Clinical Benefit in Patients Suffering From Acute Coronary Syndrome
7. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
8. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
9. Study Supports Use of GlycoMark Blood Test to Evaluate Therapy in Children with Diabetes
10. Quigley Corporation Releases Update on Quigley Pharmas Phase IIb Clinical Study of QR-333 in Diabetic Peripheral Neuropathy
11. Biodel Inc. Announces VIAject(TM) Phase II Meal Study Data at the 2007 European Association for the Study of Diabetes Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... made great strides in saving China,s endangered national treasure, ... 65 giant panda reserves that have been established and ... 1596 pandas remain in the wild. , Breeding ... the panda by improving genetic diversity, avoid inbreeding and ... are these high-profile programs doing so far? , In ...
(Date:7/23/2014)... Shimadzu Scientific Instruments has launched the ... developed jointly with Ajinomoto Co. Inc. Offering simultaneous ... amino acids in nine minutes, drastically enhancing laboratory ... utilizing a fast application-specific column and an LCMS-2020 ... even under conditions with difficult samples that contain ...
(Date:7/23/2014)... AVIV, Israel , July 23, 2014 /PRNewswire/ ... ., a portfolio company of Trendlines Agtech ... one of Israel,s leading ... http://photos.prnewswire.com/prnh/20140121/666259-a) , Valentis,s technology combines nanocrystalline ... plant pulp waste, with additional nanoparticles to produce ...
(Date:7/23/2014)... 2014  GrowBLOX Sciences, Inc. (OTCQB: GBLX), a medical cannabis ... for two medical marijuana dispensary locations in Las ... the Clark County, Nevada dispensary for ... previously announced.  GrowBLOX Sciences, CEO Craig Ellins ... applications for dispensaries in the City of Las ...
Breaking Biology Technology:Shimadzu's New UF-Amino Station Provides High-Speed, Multi-Component Analysis of Amino Acids in Food & Beverage and Pharmaceutical Testing 2Valentis Nanotech Signs MOU to Integrate Technology in Thermoplastics Production 2GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 2GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 3
... 3 ,HemoGenix(R) and ORF Genetics announce the collaboration ... for use in all HALO(R),Assay Kits and HALO(R) ... cells is detected. , ... of growth factors and cytokines using,barley seed as ...
... , QUEBEC CITY, Dec. ... AEZS ; TSX: AEZ), a global biopharmaceutical company focused ... completed the transaction under the previously announced purchase and ... relating to AEterna Zentaris, rights to royalties on future ...
... announces the exclusive licensing of DxS Scorpions™ technology to test for ... and targeted control of contaminant microbes can increase profitability. , ... ... ETS has had the exclusive license to use this technology in ...
Cached Biology Technology:HemoGenix(R), Inc Announces Implementation of ORF Genetics Human Growth Factors and Cytokines in All Human HALO(R) Assay Kits and Contract Research Services 2HemoGenix(R), Inc Announces Implementation of ORF Genetics Human Growth Factors and Cytokines in All Human HALO(R) Assay Kits and Contract Research Services 3AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners 2AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners 3ETS Laboratories Offers New Process Optimization Tools to the Fuel Ethanol Industry 2
(Date:7/23/2014)... using tissue samples cultured from cystic fibrosis patients, scientists ... Marsico Lung Institute have shown that a new CF ... CF drug. , The finding, published today in the ... mutant CFTR protein becomes unstable and loses its ability ... two drugs. The research offers several insights into how ...
(Date:7/23/2014)... , , , , ... , , , , ... extend healthy lifespan. The idea, they argue, would be to target the... , , ... , , , , , ... , , , , , , , Medicine focuses almost ...
(Date:7/23/2014)... Roughly 780 million people around the world have no ... Health Organization (WHO), 3.4 million people die from water-related ... the goal of making a contribution to solving this ... Wendelin Stark, head of the Functional Materials Laboratory, the ... developing a prototype. , "What makes our DrinkPure filter ...
Breaking Biology News(10 mins):UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 2UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 3UNC researchers find unsuspected characteristics of new CF drugs, offering potential paths to more effective therapies 4Strategy proposed for preventing diseases of aging 2Strategy proposed for preventing diseases of aging 3Strategy proposed for preventing diseases of aging 4Strategy proposed for preventing diseases of aging 5ETH student develops filter for clean water around the world 2
... Boston, MA (Jan. 18, 2012) The National ... Research Institute, a subsidiary of Mass. Eye and Ear, ... understand the origins of eye allergies (NEI Grant Number ... principal investigator for the project formally entitled "Cellular and ...
... new approach to motion capture technology is offering fresh ... general. Researchers studied three types of tennis serves, ... which creates the highest potential for shoulder injury. ... Annals of Biomedical Engineering , could aid sports training ...
... of microbiologists led by Indiana University researchers has identified a ... single end or pole of the cell instead of uniform, ... that could have implications in the development of new antibacterial ... bacteria such as Escherichia coli and Bacillus ...
Cached Biology News:Markerless motion capture offers a new angle on tennis injuries 2Markerless motion capture offers a new angle on tennis injuries 3Markerless motion capture offers a new angle on tennis injuries 4Polar growth at the bacterial scale reveals potential new targets for antibiotic therapy 2Polar growth at the bacterial scale reveals potential new targets for antibiotic therapy 3
... Microarrays designed for pathway studies, protein-protein ... (PTB) Studies built on the flexible ... platform. These microarrays are available as ... Microarray Service. Custom Probe ...
... adult normal Mega Western Protein Array was ... Mega Western Protein Arrays are manufactured using ... tissue sources. A protein sample from each ... with a Protein molecular weight marker on ...
... Multi-User Applications Package Superior Protein Detection ... The ProXPRESS 2D Proteomic Imaging System is ... proteomic and general life science research applications. ... use of all dyes in the UV ...
... includes 7 lanes of ... Alzheimer's-diseased brain tissue including: ... frontal lobe, temporal lobe, ... and cerebellum. Patent/trademark/license (electronic): ...
Biology Products: